Loading
ProMIS Neurosciences Inc. Stock: price and insider trades · United States
1 insider bought €26k of shares over the last 90 days, the latest by Kaplan Johanne, filed 07 Aug 2026.
ProMIS Neurosciences Inc.: what insiders have been doing
ProMIS Neurosciences Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 20 October 2025 and 20 October 2026, 7 insiders published 11 filings.
Only purchases show up on the open market, 6 purchases in all worth €7.4M, filed by 4 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €7.2M, the purchase published on 5 February 2026 by ABG Management Ltd. is the largest of the period. On the buying side, the filings list 3 senior executives among the declarants.
The data flag 3 purchases as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The clock since the last published purchase (7 August 2026) now reads 75 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade.
For context, the typical company on the same exchange (median of 5,455 companies) published 22 filings over the same period, against 11 filings here. The full history, which starts in 2016, counts 28 purchases against 3 sales. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -39.7 m USD.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
69
Thresholds
n/a
Buy Volume
€8M
28 ops. · all time
Sell Volume
€5,002
3 ops. · all time
Who traded when
BuySaleEugene Williams2 buys
Johanne Kaplan2 buys
ABG Management Ltd.1 buy
Max A. Milbury1 buy
Michael S. Gordon1 sale
Neil Cashman1 buy
+1 other insider
Since the insiders bought
- -44.6%Entry US$14.72 · Close 16 Oct 2026 US$8.15
- +12.2%Entry US$11.24 · Close at T+90 US$12.61
- -61.6%Entry US$23.77 · Close at T+90 US$9.13
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate ProMIS Neurosciences Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$43.05.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
US$8.15
Analyst consensus
7 analystsStrong buy
US$18.12Target US$43.05(+428%)US$98.84
Income statement
EBITDA-US$39.7M
Net income-US$39.7M0.0% margin
Valuation
PER (forward)-1.3x
P/Book1.5x
Beta-0.25
Balance sheet & cash
Market capUS$73.1M
Total debtUS$3.9M
Free Cash Flow-US$28.1M
Profitability & ownership
ROE-172.3%
ROA-81.1%
% insiders11.9%
% institutions77.2%
Last declaration on 7 August 2026
Declarations69 total
2,280 shares@ US$13.300.026% mcap38.3% of flowCommon SharesSEC:0001104659-26-092673:0
Canonical exit: 3 Nov 2026 (T+90)
4,000 shares@ US$11.330.036% mcap34.0% of flowCommon SharesSEC:0001104659-26-047977:0
Canonical exit: 21 Jul 2026 (T+90)
2,000 shares@ US$24.4046.1% of flowCommon SharesSEC:0001374339-26-000004:0
Canonical exit: 3 Jun 2026 (T+90)
1,000 shares@ US$22.5321.1% of flowCommon SharesSEC:0001374339-26-000003:0
Canonical exit: 31 May 2026 (T+90)
1,629 shares@ US$15.3530.9% of flowCommon SharesSEC:0001374339-26-000002:0
Canonical exit: 20 May 2026 (T+90)
700,741 shares@ US$12.13100.0% of flowCommon SharesSEC:0001493152-26-005410:0
Canonical exit: 4 May 2026 (T+90)
4,122 shares@ US$12.1375.0% of flowCommon SharesSEC:0001104659-26-011140:0
2,060 shares@ US$12.1330.8% of flowCommon SharesSEC:0001104659-26-011139:0
6,595 shares@ US$12.1384.2% of flowCommon SharesSEC:0001104659-26-011137:0
3,050 shares@ US$12.1327.5% of flowCommon SharesSEC:0001104659-26-011135:0
6,183 shares@ US$12.13100.0% of flowCommon SharesSEC:0001104659-26-011138:0
30,392 shares@ US$0.491215.8% of flowCommon SharesSEC:0001927056-25-000004:0
Canonical exit: 1 Jan 2026 (T+90)
697,674 sharesCommon Shares, no par valueSEC:0001104659-25-095035:0
697,674 sharesCommon Shares, no par valueSEC:0001104659-25-088246:0
48,333 sharesCommon Shares, no par valueSEC:0001104659-25-078615:0
119,800 sharesCommon Shares, no par valueSEC:0001104659-25-071857:0
119,800 sharesCommon Shares, no par valueSEC:0001104659-25-071858:0
93,223 sharesCommon Shares, no par valueSEC:0001104659-25-065292:0
15,000 shares@ US$0.97325.0% of flowCommon SharesSEC:0001374339-25-000001:0
Canonical exit: 11 May 2025 (T+90)
60,000 shares@ US$1.2511100.0% of flowCommon SharesSEC:0001374339-24-000003:0
Canonical exit: 19 Dec 2024 (T+90)
76,931 shares@ US$1.2228100.0% of flowCommon Shares, no par valueSEC:0001104659-24-100976:0
Canonical exit: 15 Dec 2024 (T+90)
10,000 shares@ US$1.24929.9% of flowCommon SharesSEC:0001374339-24-000002:0
Canonical exit: 12 Nov 2024 (T+90)
697,674 sharesCommon Shares, no par valueSEC:0001104659-24-085369:0
Canonical exit: 29 Oct 2024 (T+90)
465,116 sharesCommon Shares, no par valueSEC:0001104659-24-085371:0
Canonical exit: 29 Oct 2024 (T+90)
465,116 sharesCommon Shares, no par valueSEC:0001104659-24-085375:0
Canonical exit: 29 Oct 2024 (T+90)
25 of 69 declarations
About ProMIS Neurosciences Inc.
ProMIS Neurosciences Inc. (NASDAQ: PMN, United States) is a clinical-stage biotechnology company focused on discovering and developing therapeutic antibodies and vaccines that target misfolded proteins implicated in neurodegenerative disease. For investors, the company should be viewed as a pipeline-driven biotech rather than a revenue-generating commercial platform, meaning valuation is highly sensitive to clinical readouts, regulatory progress, and financing milestones. ProMIS was incorporated in 2004 and has long been associated with Toronto, Ontario, while also maintaining operations in Cambridge, Massachusetts. That dual footprint gives the company a North American operating base with direct access to the U.S. biotech and capital markets ecosystem. ([promisneurosciences.com](https://www.promisneurosciences.com/investors/sec-filings/content/0001558370-24-005785/pmn-20231231xars.pdf?utm_source=openai))
Strategically, ProMIS is built around a proprietary approach to toxic oligomers, especially in Alzheimer’s disease, while extending the same scientific logic to other neurodegenerative disorders. Its lead asset is PMN310, a humanized antibody designed to selectively bind toxic beta-amyloid oligomers in Alzheimer’s disease. The pipeline also includes PMN311, an Alzheimer’s vaccine candidate, and PMN442, now the lead candidate for Parkinson’s disease and other synucleinopathies. Historically, the company has also referenced programs in ALS and multiple system atrophy. The common thread across the portfolio is a selective-targeting philosophy aimed at attacking the most pathogenic protein species while potentially limiting off-target activity. ([promisneurosciences.com](https://www.promisneurosciences.com/news-media/press-releases/detail/251/promis-neurosciences-announces-second-quarter-2025?utm_source=openai))
Read moreShow less
From a competitive standpoint, ProMIS operates in a crowded and scientifically demanding segment dominated by large pharmaceutical companies and specialist biotech peers pursuing Alzheimer’s and Parkinson’s therapies. Its differentiation is primarily based on its platform claim: an antibody and vaccine strategy focused on toxic oligomer species, which could be meaningful if confirmed in human studies. However, as with most small-cap biotech names listed on the NASDAQ, the investment case remains dependent on a small number of binary catalysts and the company’s ability to fund development. Recent company updates indicate that the PRECISE-AD Phase 1b study of PMN310 is fully enrolled, with six-month assessments and interim analysis expected in 2026 and later top-line data anticipated around early 2027. ([nasdaq.com](https://www.nasdaq.com/press-release/promis-neurosciences-announces-full-year-2025-financial-results-and-provides?utm_source=openai))
Recent highlights are important for the market narrative. ProMIS selected PMN442 as its lead candidate for Parkinson’s disease and other synucleinopathies, advanced PMN310 through early clinical development, and announced a private placement financing in January 2026 that could total up to approximately $175 million to extend its cash runway and support key clinical milestones. The company also reported first-quarter 2026 financial results in May 2026, confirming continued execution on its clinical programs. For U.S. and international investors alike, PMN is best characterized as a high-risk, high-upside clinical-stage neuroscience biotech quoted on the NASDAQ in the United States, with meaningful upside if its targeted protein approach translates into human efficacy. ([promisneurosciences.com](https://www.promisneurosciences.com/investors/news-events/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private?utm_source=openai))
